Updated Guidance Improves Staging of HPV-Positive Oropharyngeal Cancer
By Elana Gotkine HealthDay Reporter
MONDAY, July 21, 2025 -- Version nine of the American Joint Committee on Cancer (AJCC) and Union for International Cancer Control staging system (AJCC9V) human papillomavirus (HPV)-positive oropharyngeal carcinoma staging classification offers improved prognostication and management compared with the eighth edition (AJCC8E), according to a multicenter registry analysis published online July 8 in The Lancet Oncology.
Allen S. Ho, M.D., from Cedars-Sinai Medical Center in Los Angeles, and colleagues divided U.S. registry data from the National Cancer Database into derivation and validation cohorts in order to reappraise HPV-positive oropharyngeal carcinoma pathological staging. A total of 14,447 adult patients across 984 facilities in the United States met the inclusion criteria and were divided into a derivation cohort and validation cohort (7,768 and 6,679 patients, respectively); patients were followed for a median of 52.4 months.
The researchers found that with each additional metastatic lymph node, mortality risk increased (hazard ratio, 1.20), up to an optimal cutoff of 4.3 lymph nodes. The association of pathological extranodal extension (pENE) with increased mortality risk was confirmed in multivariable analysis (hazard ratio, 1.47); the extent of pENE (minor versus major) was not associated with significant prognostic changes. Optimized pN and pathological tumor-node-metastasis stage categories were derived and validated in adjusted hazard ratio approaches. Compared with AJCC8E, AJCC9V staging system showed superior hazard consistency, outcome prediction, and balance, but not hazard discrimination.
"The new staging will better inform clinicians and patients about a patient's prognosis and will minimize inconsistencies in the treatments patients are offered," Ho said in a statement. "Currently, a patient diagnosed as stage 1 might be offered surgery plus radiation and chemotherapy, while another stage 1 patient may be offered surgery alone. The new guidelines will help ensure each patient receives the most appropriate treatment."
Several authors disclosed ties to the biopharmaceutical industry.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted July 2025
Read this next
Cannabis Use Disorder May Up Risk of Benign Salivary Gland Tumors
MONDAY, July 21, 2025 -- Cannabis use disorder (CUD) is associated with increased risk of benign salivary gland tumors, according to a research letter published online July 17 in...
ENDO: 1999 to 2020 Saw Significant Uptick in Obesity-Related Cancer Deaths
MONDAY, July 14, 2025 -- From 1999 to 2020, obesity-related cancer mortality increased significantly, according to a study presented at ENDO 2025, the annual meeting of the...
Immune Checkpoint Inhibitor Affordability Tied to Widening Survival Disparity
FRIDAY, July 11, 2025 -- The introduction of immune checkpoint inhibitors (ICIs) was associated with a widening survival disparity between those with private insurance and those...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.